Phaseline

Companies › Capricor

Capricor: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Neurology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Deramiocel (CAP-1002)
Allogeneic cardiosphere-derived cells
–Phase 3Muscular Dystrophies; Duchenne Muscular DystrophyMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05126758Deramiocel (CAP-1002)Phase 3Muscular DystrophiesNeurologyMar 2027
NCT04428476Deramiocel (CAP-1002)Phase 2Duchenne Muscular DystrophyNeurologyMar 2027

From the company's SEC filings

Cash and short-term investments of $238m on 2026-06-30; operating cash outflow about $123m a year; runway about 23 months at that burn, to Jun 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Stoke Therapeutics Dyne Therapeutics Navamedic Danyang Huichuang Medical Equipment Alasht Pharmed

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.